Fibroblast growth factor 3 (FGF3) is expressed in mesenchymal tissues and the gene encoding this protein is present on chromosome 11q13.
Synonyms: Anti-FGF-3; Anti-Fibroblast growth factor 3; Anti-HBGF-3; Anti-INT-2 proto-oncogene protein precursor
MDL Number: MFCD01633345
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: Fibroblast growth factor 3 (FGF3) plays a very important role in inner ear development. It activates the b splice forms of FGF receptors 1 and 2, and acts like a paracrine effector of the overlying epithelium. The secreted form of FGF3 stimulates cell growth and transformation, and the nuclear form inhibits cell proliferation and DNA synthesis. It binds to and interacts with nuclear fibroblast growth factor 3-binding protein (NoBP) which is involved in promoting cell growth. Mutations in the gene cause syndromic deafness characterized by complete labyrinthine aplasia, microtia and microdontia.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC